ERBB2 and breast carcinoma: KRISTINE (NCT02131064): The KRISTINE trial compared the efficacy of T-DM1 plus pertuzumab with docetaxel, carboplatin, trastuzumab plus pertuzumab for HER2-positive stage 2–3 breast cancer.